XML 143 R126.htm IDEA: XBRL DOCUMENT v3.24.0.1
Quarterly Financial Data (Unaudited) - Summary of Company's Revised Unaudited Quarterly Financial Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Quarterly Financial Information [Line Items]                      
Net revenues                 $ 15,846 $ 14,925 $ 15,878
Gross profit                 7,645 6,973 7,594
Net income (loss)   $ 78 $ (905) $ (253) $ (1,333) $ 63 $ (278)   (615) (2,499) 456
Net income (loss) attributable to Teva   $ 70 $ (871) $ (220) $ (1,301) $ 61 $ (251)   $ (559) $ (2,446) $ 417
Earnings per share attributable to ordinary shareholders:                      
Basic   $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23)   $ (0.5) $ (2.2) $ 0.38
Diluted   $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23)   $ (0.5) $ (2.2) $ 0.38
Adjustment                      
Quarterly Financial Information [Line Items]                      
Net revenues $ 4,457 $ 3,850 $ 3,878 $ 3,661 $ 3,884 $ 3,595 $ 3,786 $ 3,661      
Gross profit 2,416 1,851 1,796 1,582 1,770 1,669 1,794 1,740      
Net income (loss) [1] 465 78 (905) (253) (1,333) 63 (278) (952)      
Net income (loss) attributable to Teva [1] $ 461 $ 70 $ (871) $ (220) $ (1,301) $ 61 $ (251) $ (955)      
Earnings per share attributable to ordinary shareholders:                      
Basic [1] $ 0.41 $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23) $ (0.86)      
Diluted [1] $ 0.41 $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23) $ (0.86)      
[1] The data presented for the above quarterly periods (except for the three months ended March 31, 2022 and the three months ended December 31, 2023) have been revised to reflect a revision of the line items in the consolidated financial statements. See tables below and note 1b.